Veracyte, Inc. (NASDAQ:VCYT) Q1 2024 Earnings Call Transcript

Marc Stapley: Yeah. So thanks for mentioning that. And AUA, we talked a little bit about that earlier. We did have a very strong showing with a large number of abstracts and presentations. The buzz there would have been around, I’d say a couple of things, but the NCCN guidelines for sure. And metastatic, I think people are excited to have, metastatic covered and it should be. And so I think that’s one of the areas that you should think about, hopefully by the end of this year, early into next year we get an answer. And so maybe that can become a driver for 2025. As I said, I do think Decipher in and of itself across all indications that we cover and all markets is a potential growth driver for multiple years to come. Outside of that, of course, data related to bladder, muscle invasive bladder cancer, our MRD test, and of course, completion of NIGHTINGALE and further support for that as well.

And then let’s just say our IVD strategy I’ve mentioned before, but we have three products that we’re working on right now, two of which we completed in 2025 and one in 2026. And so, I think of those as being certainly not necessarily revenue drivers for the timeframe you asked about, but certainly indications of us continuing to execute and knock down some of the milestones that we’ve set.

Puneet Souda: Got it. Helpful, guys. Okay. Thank you.

Marc Stapley: Thank you.

Operator: Thank you. I’m showing no further questions at this time. I would like to now turn it back to Marc for closing remarks.

Marc Stapley: Thank you, Lauren. Appreciate it. So in closing, as you can tell, I’m excited about our strong start to 2024 and the positive signals we’re seeing in our core testing business, which bolster our confidence in the growth trajectory of Veracyte, both this year and going forward. We’re making progress towards our goal of 80% penetration in the critical markets that Decipher and Afirma serve and expect to drive significant revenue from these tests over the next few years, bridging us nicely to our numerous and exciting long-term growth drivers. I want to thank the entire Veracyte team for the work they do every day for the patients we serve all over the world. Their tireless efforts have enabled us to grow and scale our company to accommodate the significant growth that we are experiencing in our business. So thank you.

Operator: Ladies and Gentlemen, this concludes our call today. Thank you for joining us. You may now disconnect.